Utility of interim and end‐of‐treatment PET/CT in peripheral T‐cell lymphomas: A review of 124 patients |
| |
Authors: | Tarec Christoffer El‐Galaly Martin Bjerregård Pedersen Martin Hutchings Karen Juul Mylam Jakob Madsen Anne Ortved Gang Martin Bøgsted Peter de Nully Brown Annika Loft Anne Lerberg Nielsen Helle Westergreen Hendel Victor Iyer Lars Christian Gormsen |
| |
Institution: | 1. Department of Hematology, Aalborg University Hospital, Aalborg, Denmark;2. Department of Hematology, Aarhus University Hospital, Aarhus, Denmark;3. Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark;4. Department of Hematology, Odense University Hospital, Odense, Denmark;5. Department of Hematology, Herlev Hospital, Copenhagen University Hospital, Denmark;6. Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark;7. Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark;8. Department of Nuclear Medicine, Herlev Hospital, Copenhagen University Hospital, Denmark;9. Department of Nuclear Medicine, Aalborg University Hospital, Aalborg, Denmark;10. Department of Nuclear Medicine and PET Centre, Aarhus University Hospital, Aarhus, Denmark |
| |
Abstract: | According to the updated guidelines for imaging in lymphoma, 18F‐FDG positron emission tomography/computed tomography (PET/CT) is recommended for staging and evaluation of treatment response in FDG‐avid lymphomas. The purpose of the study was to evaluate the utility of PET/CT in nodal peripheral T‐cell lymphomas (PTCL). Patients with newly diagnosed nodal PTCL (peripheral T‐cell lymphoma NOS, anaplastic large‐cell lymphoma, or angioimmunoblastic T‐cell lymphoma) seen at five Danish hematology centers during the period 2006 to 2012 were included, if they had been pretherapeutically staged with PET/CT. Medical records were reviewed for baseline clinical and follow‐up information. Staging, interim (I‐PET), and end‐of‐treatment PET/CT (E‐PET) studies were centrally reviewed, and reported using the Deauville 5‐point score (DS). A total of 124 patients fulfilled the inclusion criteria. The median age was 58 years, and 88% received CHOP/CHOP‐like therapy. Five years PFS and OS of the study population was 36.8% (95% CI 27.3–46.4) and 49.7% (95% CI 38.9–59.6), respectively. The presence of PET/CT‐ascertained lung and/or liver involvement was associated with a worse outcome. The sensitivity of PET/CT for detecting biopsy‐defined bone marrow involvement was only 18% (95% CI 4–43). An interim DS >3 was not prognostic for worse OS and PFS among CHOP/CHOP‐like treated patients in uni‐ or multivariate analyses. A DS >3 after treatment predicted a worse prognosis. In conclusion, I‐PET was not predictive of outcome in CHOP/CHOP‐like treated PTCL patients when using the DS. Prospective studies are needed to determine the optimal use of PET/CT in PTCL including the role of quantitative PET/CT analysis. Am. J. Hematol. 90:975–980, 2015. © 2015 Wiley Periodicals, Inc. |
| |
Keywords: | |
|
|